1
|
Bakshi R, Thompson AJ, Rocca MA, Pelletier
D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA and
Filippi M: MRI in multiple sclerosis: Current status and future
prospects. Lancet Neurol. 7:615–625. 2008.PubMed/NCBI View Article : Google Scholar
|
2
|
Lassmann H: Targets of therapy in
progressive MS. Mult Scler. 23:1593–1599. 2017.PubMed/NCBI View Article : Google Scholar
|
3
|
Lassmann H: Pathogenic mechanisms
associated with different clinical courses of multiple sclerosis.
Front Immunol. 9(3116)2019.PubMed/NCBI View Article : Google Scholar
|
4
|
Haider L, Simeonidou C, Steinberger G,
Hametner S, Grigoriadis N, Deretzi G, Kovacs GG, Kutzelnigg A,
Lassmann H and Frischer JM: Multiple sclerosis deep grey matter:
The relation between demyelination, neurodegeneration, inflammation
and iron. J Neurol Neurosurg Psychiatry. 85:1386–1395.
2014.PubMed/NCBI View Article : Google Scholar
|
5
|
Minagar A, Barnett MH, Benedict RHB,
Pelletier D, Pirko I, Sahraian MA, Frohman E and Zivadinov R: The
thalamus and multiple sclerosis: Modern views on pathologic,
imaging, and clinical aspects. Neurology. 80:210–219.
2013.PubMed/NCBI View Article : Google Scholar
|
6
|
Houtchens MK, Benedict RHB, Killiany R,
Sharma J, Jaisani Z, Singh B, Weinstock-Guttman B, Guttmann CR and
Bakshi R: Thalamic atrophy and cognition in multiple sclerosis.
Neurology. 69:1213–1223. 2007.PubMed/NCBI View Article : Google Scholar
|
7
|
Miller DH, Chard DT and Ciccarelli O:
Clinically isolated syndromes. Lancet Neurol. 11:157–169.
2012.PubMed/NCBI View Article : Google Scholar
|
8
|
Brownlee WJ and Miller DH: Clinically
isolated syndromes and the relationship to multiple sclerosis. J
Clin Neurosci. 21:2065–2071. 2014.PubMed/NCBI View Article : Google Scholar
|
9
|
Lin A, Ross BD, Harris K and Wong W:
Efficacy of proton magnetic resonance spectroscopy in neurological
diagnosis and neurotherapeutic decision making. NeuroRx. 2:197–214.
2005.PubMed/NCBI View Article : Google Scholar
|
10
|
Swanberg KM, Landheer K, Pitt D and Juchem
C: Quantifying the metabolic signature of multiple sclerosis by in
vivo proton magnetic resonance spectroscopy: Current challenges and
future outlook in the translation from proton signal to diagnostic
biomarker. Front Neurol. 10(1173)2019.PubMed/NCBI View Article : Google Scholar
|
11
|
Oh J, Ontaneda D, Azevedo C, Klawiter EC,
Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey
B, et al: Imaging outcome measures of neuroprotection and repair in
MS: A consensus statement from NAIMS. Neurology. 92:519–533.
2019.PubMed/NCBI View Article : Google Scholar
|
12
|
Wilson M, Andronesi O, Barker PB, Bartha
R, Bizzi A, Bolan PJ, Brindle KM, Choi IY, Cudalbu C, Dydak U, et
al: Methodological consensus on clinical proton MRS of the brain:
Review and recommendations. Magn Reson Med. 82:527–550.
2019.PubMed/NCBI View Article : Google Scholar
|
13
|
Bitsch A, Bruhn H, Vougioukas V,
Stringaris A, Lassmann H, Frahm J and Brück W: Inflammatory CNS
demyelination: Histopathologic correlation with in vivo
quantitative proton MR spectroscopy. AJNR Am J Neuroradiol.
20:1619–1627. 1999.PubMed/NCBI
|
14
|
Rae CD: A guide to the metabolic pathways
and function of metabolites observed in human brain 1H magnetic
resonance spectra. Neurochem Res. 39:1–36. 2014.PubMed/NCBI View Article : Google Scholar
|
15
|
Geurts JJG, Reuling IEW, Vrenken H,
Uitdehaag BMJ, Polman CH, Castelijns JA, Barkhof F and Pouwels PJW:
MR spectroscopic evidence for thalamic and hippocampal, but not
cortical, damage in multiple sclerosis. Magn Reson Med. 55:478–483.
2006.PubMed/NCBI View Article : Google Scholar
|
16
|
Zhu H and Barker PB: MR spectroscopy and
spectroscopic imaging of the brain. Methods Mol Biol. 711:203–226.
2011.PubMed/NCBI View Article : Google Scholar
|
17
|
Buonocore MH and Maddock RJ: Magnetic
resonance spectroscopy of the brain: A review of physical
principles and technical methods. Rev Neurosci. 26:609–632.
2015.PubMed/NCBI View Article : Google Scholar
|
18
|
Nordengen K, Heuser C, Rinholm JE, Matalon
R and Gundersen V: Localisation of N-acetylaspartate in
oligodendrocytes/myelin. Brain Struct Funct. 220:899–917.
2015.PubMed/NCBI View Article : Google Scholar
|
19
|
Narayana PA: Magnetic resonance
spectroscopy in the monitoring of multiple sclerosis. J
Neuroimaging. 15 (Suppl 4):46S–57S. 2005.PubMed/NCBI View Article : Google Scholar
|
20
|
Scheau C, Preda EM, Popa GA, Ghergus AE,
Capsa RA and Lupescu IG: Magnetic resonance spectroscopy-a
non-invasive method in evaluating focal and diffuse central nervous
system disease. J Med Life. 5:423–427. 2012.PubMed/NCBI
|
21
|
Hertz L: Intercellular metabolic
compartmentation in the brain: Past, present and future. Neurochem
Int. 45:285–296. 2004.PubMed/NCBI View Article : Google Scholar
|
22
|
Srinivasan R, Sailasuta N, Hurd R, Nelson
S and Pelletier D: Evidence of elevated glutamate in multiple
sclerosis using magnetic resonance spectroscopy at 3 T. Brain.
128:1016–1025. 2005.PubMed/NCBI View Article : Google Scholar
|
23
|
Nantes JC, Proulx S, Zhong J, Holmes SA,
Narayanan S, Brown RA, Hoge RD and Koski L: GABA and glutamate
levels correlate with MTR and clinical disability: Insights from
multiple sclerosis. Neuroimage. 157:705–715. 2017.PubMed/NCBI View Article : Google Scholar
|
24
|
Muhlert N, Atzori M, De Vita E, Thomas DL,
Samson RS, Wheeler-Kingshott CAM, Geurts JJ, Miller DH, Thompson AJ
and Ciccarelli O: Memory in multiple sclerosis is linked to
glutamate concentration in grey matter regions. J Neurol Neurosurg
Psychiatry. 85:834–840. 2014.PubMed/NCBI View Article : Google Scholar
|
25
|
Mader I, Roser W, Kappos L, Hagberg G,
Seelig J, Radue EW and Steinbrich W: Serial proton MR spectroscopy
of contrast-enhancing multiple sclerosis plaques: Absolute
metabolic values over 2 years during a clinical pharmacological
study. Am J Neuroradiol. 21:1220–1227. 2000.PubMed/NCBI
|
26
|
Vafaeyan H, Ebrahimzadeh SA, Rahimian N,
Alavijeh SK, Madadi A, Faeghi F, Harirchian MH and Rad HS:
Quantification of diagnostic biomarkers to detect multiple
sclerosis lesions employing (1)H-MRSI at 3T. Australas Phys Eng Sci
Med. 38:611–618. 2015.PubMed/NCBI View Article : Google Scholar
|
27
|
Cooper AJL: Role of astrocytes in
maintaining cerebral glutathione homeostasis and in protecting the
brain against xenobiotics and oxidative stress. In: Glutathione in
the Nervous System. CRC Press, pp91-115, 2020.
|
28
|
Rice ME and Russo-Menna I: Differential
compartmentalization of brain ascorbate and glutathione between
neurons and glia. Neuroscience. 82:1213–1223. 1998.PubMed/NCBI View Article : Google Scholar
|
29
|
Choi I, Lee P, Hughes AJ, Denney DR and
Lynch SG: Longitudinal changes of cerebral glutathione (GSH) levels
associated with the clinical course of disease progression in
patients with secondary progressive multiple sclerosis. Mult Scler.
23:956–562. 2017.PubMed/NCBI View Article : Google Scholar
|
30
|
Choi IY, Lee SP, Denney D and Lynch S:
Lower levels of glutathione in the brains of secondary progressive
multiple sclerosis patients measured by 1H magnetic resonance
chemical shift imaging at 3 T. Mult Scler. 17:289–296.
2011.PubMed/NCBI View Article : Google Scholar
|
31
|
Filippi M, Bozzali M, Rovaris M, Gonen O,
Kesavadas C, Ghezzi A, Martinelli V, Grossman RI, Scotti G, Comi G
and Falini A: Evidence for widespread axonal damage at the earliest
clinical stage of multiple sclerosis. Brain. 126:433–437.
2003.PubMed/NCBI View Article : Google Scholar
|
32
|
Wattjes MP, Harzheim M, Lutterbey GG,
Klotz L, Schild HH and Träber F: Axonal damage but no increased
glial cell activity in the normal-appearing white matter of
patients with clinically isolated syndromes suggestive of multiple
sclerosis using high-field magnetic resonance spectroscopy. Am J
Neuroradiol. 28:1517–1522. 2007.PubMed/NCBI View Article : Google Scholar
|
33
|
Brex PA, Gomez-Anson B, Parker GJ,
Molyneux PD, Miszkiel KA, Barker GJ, MacManus DG, Davie CA, Plant
GT and Miller DH: Proton MR spectroscopy in clinically isolated
syndromes suggestive of multiple sclerosis. J Neurol Sci.
166:16–22. 1999.PubMed/NCBI View Article : Google Scholar
|
34
|
Wattjes MP, Harzheim M, Lutterbey GG,
Bogdanow M, Schild HH and Träber F: High field MR imaging and 1H-MR
spectroscopy in clinically isolated syndromes suggestive of
multiple sclerosis: Correlation between metabolic alterations and
diagnostic MR imaging criteria. J Neurol. 255:56–63.
2008.PubMed/NCBI View Article : Google Scholar
|
35
|
Fernando KTM, McLean MA, Chard DT,
MacManus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson
AJ and Miller DH: Elevated white matter myo-inositol in clinically
isolated syndromes suggestive of multiple sclerosis. Brain.
127:1361–1369. 2004.PubMed/NCBI View Article : Google Scholar
|
36
|
Miller DH, Weinshenker BG, Filippi M,
Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M,
Johnson RT, Kappos L, et al: Differential diagnosis of suspected
multiple sclerosis: A consensus approach. Mult Scler. 14:1157–1174.
2008.PubMed/NCBI View Article : Google Scholar
|
37
|
Polman CH, Reingold SC, Banwell B, Clanet
M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M,
Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2010
Revisions to the McDonald criteria. Ann Neurol. 69:292–302.
2011.PubMed/NCBI View Article : Google Scholar
|
38
|
Kurtzke JF: Rating neurologic impairment
in multiple sclerosis: An expanded disability status scale (EDSS).
Neurology. 33:1444–1452. 1983.PubMed/NCBI View Article : Google Scholar
|
39
|
Wilson M, Reynolds G, Kauppinen RA,
Arvanitis TN and Peet AC: A constrained least-squares approach to
the automated quantitation of in vivo ¹H magnetic resonance
spectroscopy data. Magn Reson Med. 65:1–12. 2011.PubMed/NCBI View Article : Google Scholar
|
40
|
Reynolds G, Wilson M, Peet A and Arvanitis
TN: An algorithm for the automated quantitation of metabolites in
in vitro NMR signals. Magn Reson Med. 56:1211–1219. 2006.PubMed/NCBI View Article : Google Scholar
|
41
|
Ramadan S, Lin A and Stanwell P: Glutamate
and glutamine: A review of in vivo MRS in the human brain. NMR
Biomed. 26:1630–1646. 2013.PubMed/NCBI View Article : Google Scholar
|
42
|
Hancu I: Optimized glutamate detection at
3T. J Magn Reson Imaging. 30:1155–1162. 2009.PubMed/NCBI View Article : Google Scholar
|
43
|
Walls AB, Waagepetersen HS, Bak LK,
Schousboe A and Sonnewald U: The glutamine-glutamate/GABA cycle:
Function, regional differences in glutamate and GABA production and
effects of interference with GABA metabolism. Neurochem Res.
40:402–409. 2015.PubMed/NCBI View Article : Google Scholar
|
44
|
Zhang Y and Shen J: Regional and
tissue-specific differences in brain glutamate concentration
measured by in vivo single voxel MRS. J Neurosci Methods.
239:94–99. 2015.PubMed/NCBI View Article : Google Scholar
|
45
|
Baker EH, Basso G, Barker PB, Smith MA,
Bonekamp D and Horská A: Regional apparent metabolite
concentrations in young adult brain measured by (1)H MR
spectroscopy at 3 Tesla. J Magn Reson Imaging. 27:489–499.
2008.PubMed/NCBI View Article : Google Scholar
|
46
|
Chard DT, Griffin CM, McLean MA, Kapeller
P, Kapoor R, Thompson AJ and Miller DH: Brain metabolite changes in
cortical grey and normal-appearing white matter in clinically early
relapsing-remitting multiple sclerosis. Brain. 125:2342–2352.
2002.PubMed/NCBI View Article : Google Scholar
|
47
|
Sastre-Garriga J, Ingle GT, Chard DT,
Ramió-Torrentà L, McLean MA, Miller DH and Thompson AJ: Metabolite
changes in normal-appearing gray and white matter are linked with
disability in early primary progressive multiple sclerosis. Arch
Neurol. 62:569–573. 2005.PubMed/NCBI View Article : Google Scholar
|
48
|
Swanberg KM, Prinsen H, DeStefano K,
Bailey M, Kurada AV, Pitt D, Fulbright RK and Juchem C: In vivo
evidence of differential frontal cortex metabolic abnormalities in
progressive and relapsing-remitting multiple sclerosis. NMR Biomed.
34(e4590)2021.PubMed/NCBI View Article : Google Scholar
|
49
|
Tisell A, Leinhard OD, Warntjes JBM, Aalto
A, Smedby Ö, Landtblom AM and Lundberg P: Increased concentrations
of glutamate and glutamine in normal-appearing white matter of
patients with multiple sclerosis and normal MR imaging brain scans.
PLoS One. 8(e61817)2013.PubMed/NCBI View Article : Google Scholar
|
50
|
Macmillan EL, Tam R, Zhao Y, Vavasour IM,
Li DKB, Oger J, Freedman MS, Kolind SH and Traboulsee AL:
Progressive multiple sclerosis exhibits decreasing glutamate and
glutamine over two years. Mult Scler. 22:112–116. 2016.PubMed/NCBI View Article : Google Scholar
|
51
|
Azevedo CJ, Kornak J, Chu P, Sampat M,
Okuda DT, Cree BA, Nelson SJ, Hauser SL and Pelletier D: In vivo
evidence of glutamate toxicity in multiple sclerosis. Ann Neurol.
76:269–278. 2014.PubMed/NCBI View Article : Google Scholar
|
52
|
Cecil KM: Proton magnetic resonance
spectroscopy: Technique for the Neuroradiologist. Neuroimaging Clin
N Am. 23:381–392. 2013.PubMed/NCBI View Article : Google Scholar
|
53
|
Gustafsson MC, Dahlqvist O, Jaworski J,
Lundberg P and Landtblom AME: Low choline concentrations in
normal-appearing white matter of patients with multiple sclerosis
and normal MR imaging brain scans. Am J Neuroradiol. 28:1306–1312.
2007.PubMed/NCBI View Article : Google Scholar
|
54
|
Mathiesen HK, Tscherning T, Sorensen PS,
Larsson HBW, Rostrup E, Paulson OB and Hanson LG: Multi-slice
echo-planar spectroscopic MR imaging provides both global and local
metabolite measures in multiple sclerosis. Magn Reson Med.
53:750–759. 2005.PubMed/NCBI View Article : Google Scholar
|
55
|
Su K, Bourdette D and Forte M:
Mitochondrial dysfunction and neurodegeneration in multiple
sclerosis. Front Physiol. 4(169)2013.PubMed/NCBI View Article : Google Scholar
|
56
|
Moffett JR, Ross B, Arun P, Madhavarao CN
and Namboodiri AMA: N-Acetylaspartate in the CNS: From
neurodiagnostics to neurobiology. Prog Neurobiol. 81:89–131.
2007.PubMed/NCBI View Article : Google Scholar
|
57
|
Polacek H, Kantorova E, Hnilicova P,
Grendar M, Zelenak K and Kurca E: Increased glutamate and deep
brain atrophy can predict the severity of multiple sclerosis.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 163:45–53.
2019.PubMed/NCBI View Article : Google Scholar
|
58
|
Werner P, Pitt D and Raine CS: Multiple
sclerosis: Altered glutamate homeostasis in lesions correlates with
oligodendrocyte and axonal damage. Ann Neurol. 50:169–180.
2001.PubMed/NCBI View Article : Google Scholar
|
59
|
Kostic M, Zivkovic N and Stojanovic I:
Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci.
24:71–88. 2013.PubMed/NCBI View Article : Google Scholar
|
60
|
Witte ME, Bø L, Rodenburg RJ, Belien JA,
Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries
HE, et al: Enhanced number and activity of mitochondria in multiple
sclerosis lesions. J Pathol. 219:193–204. 2009.PubMed/NCBI View Article : Google Scholar
|
61
|
Blokhin A, Vyshkina T, Komoly S and Kalman
B: Variations in mitochondrial DNA copy numbers in MS brains. J Mol
Neurosci. 35:283–287. 2008.PubMed/NCBI View Article : Google Scholar
|
62
|
Dutta R, McDonough J, Yin X, Peterson J,
Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, et al:
Mitochondrial dysfunction as a cause of axonal degeneration in
multiple sclerosis patients. Ann Neurol. 59:478–489.
2006.PubMed/NCBI View Article : Google Scholar
|
63
|
Paling D, Golay X, Wheeler-Kingshott C,
Kapoor R and Miller D: Energy failure in multiple sclerosis and its
investigation using MR techniques. J Neurol. 258:2113–2127.
2011.PubMed/NCBI View Article : Google Scholar
|
64
|
Van Horssen J, Witte ME, Schreibelt G and
de Vries HE: Radical changes in multiple sclerosis pathogenesis.
Biochim Biophys Acta. 1812:141–150. 2011.PubMed/NCBI View Article : Google Scholar
|
65
|
McKenna MC: The glutamate-glutamine cycle
is not stoichiometric: Fates of glutamate in brain. J Neurosci Res.
85:3347–3358. 2007.PubMed/NCBI View Article : Google Scholar
|
66
|
Koga M, Serritella AV, Messmer MM,
Hayashi-Takagi A, Hester LD, Snyder SH, Sawa A and Sedlak TW:
Glutathione is a physiologic reservoir of neuronal glutamate.
Biochem Biophys Res Commun. 409:596–602. 2011.PubMed/NCBI View Article : Google Scholar
|
67
|
Sedlak TW, Paul BD, Parker GM, Hester LD,
Snowman AM, Taniguchi Y, Kamiya A, Snyder SH and Sawa A: The
glutathione cycle shapes synaptic glutamate activity. Proc Natl
Acad Sci USA. 116:2701–2706. 2019.PubMed/NCBI View Article : Google Scholar
|